Juan Lantero Rodriguez

List of Publications by Year
in descending order

33	3,059	279798 23	414414 32
papers	citations	h-index	g-index

33	33	33	2025
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	10.2	668
2	Plasma p-tau231: a new biomarker for incipient Alzheimerâ€™s disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
3	Plasma p-tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8Âyears prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica, 2020, 140, 267-278.	7.7	209
4	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimerâ€™s continuum when only subtle changes in AÎ² pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
5	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimerâ€™s Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	7.9	186
6	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
7	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
8	Time course of phosphorylated-tau181 in blood across the Alzheimerâ€™s disease spectrum. Brain, 2021, 144, 325-339.	7.6	124
9	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews Neurology, 2022, 18, 400-418.	10.1	99
10	Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	1.9	93
11	Plasma biomarkers for Alzheimerâ€™s Disease in relation to neuropathology and cognitive change. Acta Neuropathologica, 2022, 143, 487-503.	7.7	89
12	Headâ€toâ€head comparison of clinical performance of CSF phosphoâ€tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's and Dementia, 2021, 17, 755-767.	0.8	81
13	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimerâ€™s disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
14	Biomarker modeling of Alzheimerâ€™s disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	11.6	73
15	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	6.1	65
16	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 77, 1129-1141.	2.6	55
17	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54
18	OUP accepted manuscript. Brain, 2021, 144, 434-449.	7.6	54

#	Article	IF	Citations
19	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.1	50
20	Plasma pâ€tau231, pâ€tau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	5.3	42
21	Association between polygenic risk score of Alzheimerâ€™s disease and plasma phosphorylated tau in individuals from the Alzheimerâ€™s Disease Neuroimaging Initiative. Alzheimer's Research and Therapy, 2021, 13, 17.	6.2	35
22	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 69.	6.2	34
23	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimerâ€™s disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	12.8	33
24	Pâ€tau235: a novel biomarker for staging preclinical Alzheimerâ€™s disease. EMBO Molecular Medicine, 2021, 13, e15098.	6.9	30
25	CSF biomarkers and plasma pâ€tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.8	22
26	AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia, 2017, 60, 729-739.	6.3	20
27	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	7.6	20
28	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	5.2	17
29	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	3.3	15
30	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Communications Biology, 2021, 4, 1265.	4.4	4
31	Plasma pâ€tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8 years prior to postâ€mortem and improves the clinical characterisation of cognitive decline. Alzheimer's and Dementia, 2020, 16, e047539.	0.8	2
32	Distinctive effect of biological sex in ADâ€related CSF and plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.8	2
33	Population-based blood screening for pre-clinical Alzheimerâ€™s disease: a British birth cohort at age 70. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A91.2-A91.	1.9	0